Launch & Patient Access Plenary 'Time To Smooth Out The Pavement & Build More lanes: Preparing for the Cell & Gene Therapy Rush'
Friday, May 31, 2024 01:45 PM - 03:15 PM
Plenary Hall
Launch and Patient Access
Plenary Session
Chair
Building upon the experience of late-stage and commercial stakeholders, the session progresses operational excellence and broader patient access to CGTs by serving as a collaborative platform to build the roadmap for maturing our field. As a community, we recognize the clinical and commercial milestones, and celebrate the transformational impact for patients, but we remain committed to addressing the challenges.
This Plenary session will feature experiences and considerations towards operational execution, challenges and concerns about cell/gene/tissue-based therapies for society, and insights into these therapies as viable and sustainable models. Bring your thinking caps to learn, and your hard hats to get to work so that we can continue to pave the future of cell and gene therapies.
- Aby J. Mathew, PhD, BioLife Solutions, Inc., United States
- Timothy Moore, MEng, Allogene Therapeutics, United States, "Allogenic Cell Therapy Technology"
- Francesco Dazzi, MD, PhD, AstraZeneca, United Kingdom, "The Hurdles to Patients' Access"
- Tom Whitehead, Emily Whitehead Foundation, United States "The Whitehead’s path to a Car-T Cure and now Paving it Forward"
- Emily Whitehead, Emily Whitehead Foundation, United States, "The Whitehead’s path to a Car-T Cure and now Faving it Forward"
- Nicole Verdun, MD, FDA, United States
Building upon the experience of late-stage and commercial stakeholders, the session progresses operational excellence and broader patient access to CGTs by serving as a collaborative platform to build the roadmap for maturing our field. As a community, we recognize the clinical and commercial milestones, and celebrate the transformational impact for patients, but we remain committed to addressing the challenges.
This Plenary session will feature experiences and considerations towards operational execution, challenges and concerns about cell/gene/tissue-based therapies for society, and insights into these therapies as viable and sustainable models. Bring your thinking caps to learn, and your hard hats to get to work so that we can continue to pave the future of cell and gene therapies.
